The Synthetic Oral Cancer Prediction Dataset is designed for educational and research purposes to analyse factors associated with oral cancer risk, progression, and treatment outcomes. The dataset includes anonymised, synthetic data on various clinical, lifestyle, and demographic factors for individuals diagnosed with oral cancer.

Dataset Features

• ID: Unique identifier for each participant.
• Country: Country of residence of the participant.
• Age: Age of the participant (in years).
• Gender: Gender of the participant (Male/Female).
• Tobacco Use: History of tobacco use (Yes/No).
• Alcohol Consumption: History of alcohol consumption (Yes/No).
• HPV Infection: Presence of human papillomavirus infection (Yes/No).
• Betel Quid Use: History of Betel quid use (Yes/No).
• Chronic Sun Exposure: History of chronic sun exposure (Yes/No).
• Poor Oral Hygiene: Poor oral hygiene habits (Yes/No).
• Diet (Fruits & Vegetables Intake): Frequency of consuming fruits and vegetables (Yes/No).
• Family History of Cancer: Family history of cancer (Yes/No).
• Compromised Immune System: Whether the participant has a compromised immune system (Yes/No).
• Oral Lesions: Presence of oral lesions (Yes/No).
• Unexplained Bleeding: Presence of unexplained bleeding (Yes/No).
• Difficulty Swallowing: Difficulty in swallowing (Yes/No).
• White or Red Patches in Mouth: Presence of white or red patches in the mouth (Yes/No).
• Tumor Size (cm): Size of the tumor in centimeters.
• Cancer Stage: Stage of the oral cancer (1-4).
• Treatment Type: Type of treatment received (e.g., Surgery, Radiation, Chemotherapy).
• Survival Rate (5-Year, %): 5-year survival rate in percentage.
• Cost of Treatment (USD): Total cost of treatment in USD.
• Economic Burden (Lost Workdays per Year): Economic burden due to lost workdays each year.
• Early Diagnosis: Whether early diagnosis was made (Yes/No).
• Oral Cancer (Diagnosis): Diagnosis of oral cancer (Yes/No).

Distribution

https://storage.googleapis.com/opendatabay_public/09f348fc-a2e8-4132-9f1b-195765d80afc/622bf59174d1_plot_output.png" alt="Synthetic oral cancer dataset plot_output.png">

Usage

This dataset can be used for the following applications:

• Cancer Research: Investigate the relationship between various lifestyle, clinical, and demographic factors with oral cancer risk and progression.
• Predictive Modeling: Build machine learning models to predict cancer diagnosis, survival rate, or treatment outcomes based on participant data.
• Healthcare and Public Health: Study the impact of lifestyle factors (e.g., tobacco, alcohol, diet) on the development and progression of oral cancer.
• Educational Purposes: Provide a dataset for students and researchers in oncology, medical data science, and public health fields to analyze cancer risk factors and treatment outcomes.

Coverage

This synthetic dataset is fully anonymized and complies with data privacy standards. It includes a wide array of factors that support diverse research and analysis in the oncology and public health domains.

License

CC0 (Public Domain)

Who Can Use It

• Cancer Researchers: To explore correlations between lifestyle factors, clinical features, and treatment outcomes in oral cancer.
• Oncologists and Healthcare Providers: To analyze the effectiveness of different treatments and factors that affect prognosis and survival.
• Public Health Professionals: To study the broader societal and economic impacts of oral cancer and develop preventive measures.
• Data Scientists and Machine Learning Practitioners: To develop predictive models for diagnosing oral cancer and improving treatment planning.
• Educators and Students: As a resource for studying cancer risk analysis, healthcare data science, and public health analytics.

Cervical Cancer Risk Factors for Biopsy: This Dataset is Obtained from UCI Repository and kindly acknowledged! This file contains a List of Risk Factors for Cervical Cancer leading to a Biopsy Examination! About 11,000 new cases of invasive cervical cancer are diagnosed each year in the U.S. However, the number of new cervical cancer cases has been declining steadily over the past decades. Although it is the most preventable type of cancer, each year cervical cancer kills about 4,000 women in the U.S. and about 300,000 women worldwide. In the United States, cervical cancer mortality rates plunged by 74% from 1955 - 1992 thanks to increased screening and early detection with the Pap test. AGE Fifty percent of cervical cancer diagnoses occur in women ages 35 - 54, and about 20% occur in women over 65 years of age. The median age of diagnosis is 48 years. About 15% of women develop cervical cancer between the ages of 20 - 30. Cervical cancer is extremely rare in women younger than age 20. However, many young women become infected with multiple types of human papilloma virus, which then can increase their risk of getting cervical cancer in the future. Young women with early abnormal changes who do not have regular examinations are at high risk for localized cancer by the time they are age 40, and for invasive cancer by age 50. SOCIOECONOMIC AND ETHNIC FACTORS Although the rate of cervical cancer has declined among both Caucasian and African-American women over the past decades, it remains much more prevalent in African-Americans -- whose death rates are twice as high as Caucasian women. Hispanic American women have more than twice the risk of invasive cervical cancer as Caucasian women, also due to a lower rate of screening. These differences, however, are almost certainly due to social and economic differences. Numerous studies report that high poverty levels are linked with low screening rates. In addition, lack of health insurance, limited transportation, and language difficulties hinder a poor woman’s access to screening services. HIGH SEXUAL ACTIVITY Human papilloma virus (HPV) is the main risk factor for cervical cancer. In adults, the most important risk factor for HPV is sexual activity with an infected person. Women most at risk for cervical cancer are those with a history of multiple sexual partners, sexual intercourse at age 17 years or younger, or both. A woman who has never been sexually active has a very low risk for developing cervical cancer. Sexual activity with multiple partners increases the likelihood of many other sexually transmitted infections (chlamydia, gonorrhea, syphilis).Studies have found an association between chlamydia and cervical cancer risk, including the possibility that chlamydia may prolong HPV infection. FAMILY HISTORY Women have a higher risk of cervical cancer if they have a first-degree relative (mother, sister) who has had cervical cancer. USE OF ORAL CONTRACEPTIVES Studies have reported a strong association between cervical cancer and long-term use of oral contraception (OC). Women who take birth control pills for more than 5 - 10 years appear to have a much higher risk HPV infection (up to four times higher) than those who do not use OCs. (Women taking OCs for fewer than 5 years do not have a significantly higher risk.) The reasons for this risk from OC use are not entirely clear. Women who use OCs may be less likely to use a diaphragm, condoms, or other methods that offer some protection against sexual transmitted diseases, including HPV. Some research also suggests that the hormones in OCs might help the virus enter the genetic material of cervical cells. HAVING MANY CHILDREN Studies indicate that having many children increases the risk for developing cervical cancer, particularly in women infected with HPV. SMOKING Smoking is associated with a higher risk for precancerous changes (dysplasia) in the cervix and for progression to invasive cervical cancer, especially for women infected with HPV. IMMUNOSUPPRESSION Women with weak immune systems, (such as those with HIV / AIDS), are more susceptible to acquiring HPV. Immunocompromised patients are also at higher risk for having cervical precancer develop rapidly into invasive cancer. DIETHYLSTILBESTROL (DES) From 1938 - 1971, diethylstilbestrol (DES), an estrogen-related drug, was widely prescribed to pregnant women to help prevent miscarriages. The daughters of these women face a higher risk for cervical cancer. DES is no longer prsecribed.

About Dataset

The dataset contains 2 .csv files This file contains various demographic and health-related data for different regions. Here's a brief description of each column:

File 1st

• avganncount: Average number of cancer cases diagnosed annually.

• avgdeathsperyear: Average number of deaths due to cancer per year.

• target_deathrate: Target death rate due to cancer.

• incidencerate: Incidence rate of cancer.

• medincome: Median income in the region.

• popest2015: Estimated population in 2015.

• povertypercent: Percentage of population below the poverty line.

• studypercap: Per capita number of cancer-related clinical trials conducted.

• binnedinc: Binned median income.

• medianage: Median age in the region.

• pctprivatecoveragealone: Percentage of population covered by private health insurance alone.

• pctempprivcoverage: Percentage of population covered by employee-provided private health insurance.

• pctpubliccoverage: Percentage of population covered by public health insurance.

• pctpubliccoveragealone: Percentage of population covered by public health insurance only.

• pctwhite: Percentage of White population.

• pctblack: Percentage of Black population.

• pctasian: Percentage of Asian population.

• pctotherrace: Percentage of population belonging to other races.

• pctmarriedhouseholds: Percentage of married households. birthrate: Birth rate in the region.

File 2nd

This file contains demographic information about different regions, including details about household size and geographical location. Here's a description of each column:

• statefips: The FIPS code representing the state.

• countyfips: The FIPS code representing the county or census area within the state.

• avghouseholdsize: The average household size in the region.

• geography: The geographical location, typically represented as the county or census area name followed by the state name.

Each row in the file represents a specific region, providing details about household size and geographical location. This information can be used for various demographic analyses and studies.

Analysis of ‘🎗️ Cancer Rates by U.S. State’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://www.kaggle.com/yamqwe/cancer-rates-by-u-s-statee on 13 February 2022.

--- Dataset description provided by original source is as follows ---

About this dataset

In the following maps, the U.S. states are divided into groups based on the rates at which people developed or died from cancer in 2013, the most recent year for which incidence data are available.

The rates are the numbers out of 100,000 people who developed or died from cancer each year.

Incidence Rates by State
The number of people who get cancer is called cancer incidence. In the United States, the rate of getting cancer varies from state to state.

• *Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population.

• ‡Rates are not shown if the state did not meet USCS publication criteria or if the state did not submit data to CDC.

• †Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2016. Available at: http://www.cdc.gov/uscs.

Death Rates by State
Rates of dying from cancer also vary from state to state.

• *Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population.

• †Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2016. Available at: http://www.cdc.gov/uscs.

Source: https://www.cdc.gov/cancer/dcpc/data/state.htm

This dataset was created by Adam Helsinger and contains around 100 samples along with Range, Rate, technical information and other features such as: - Range - Rate - and more.

How to use this dataset

• Analyze Range in relation to Rate
• Study the influence of Range on Rate
• More datasets

Acknowledgements

If you use this dataset in your research, please credit Adam Helsinger

Start A New Notebook!

--- Original source retains full ownership of the source dataset ---

SUMMARYThis analysis, designed and executed by Ribble Rivers Trust, identifies areas across England with the greatest levels of cancer (in persons of all ages). Please read the below information to gain a full understanding of what the data shows and how it should be interpreted.ANALYSIS METHODOLOGYThe analysis was carried out using Quality and Outcomes Framework (QOF) data, derived from NHS Digital, relating to cancer (in persons of all ages).This information was recorded at the GP practice level. However, GP catchment areas are not mutually exclusive: they overlap, with some areas covered by 30+ GP practices. Therefore, to increase the clarity and usability of the data, the GP-level statistics were converted into statistics based on Middle Layer Super Output Area (MSOA) census boundaries.The percentage of each MSOA’s population (all ages) with cancer was estimated. This was achieved by calculating a weighted average based on:The percentage of the MSOA area that was covered by each GP practice’s catchment areaOf the GPs that covered part of that MSOA: the percentage of registered patients that have that illness The estimated percentage of each MSOA’s population with cancer was then combined with Office for National Statistics Mid-Year Population Estimates (2019) data for MSOAs, to estimate the number of people in each MSOA with cancer, within the relevant age range.Each MSOA was assigned a relative score between 1 and 0 (1 = worst, 0 = best) based on:A) the PERCENTAGE of the population within that MSOA who are estimated to have cancerB) the NUMBER of people within that MSOA who are estimated to have cancerAn average of scores A & B was taken, and converted to a relative score between 1 and 0 (1= worst, 0 = best). The closer to 1 the score, the greater both the number and percentage of the population in the MSOA that are estimated to have cancer, compared to other MSOAs. In other words, those are areas where it’s estimated a large number of people suffer from cancer, and where those people make up a large percentage of the population, indicating there is a real issue with cancer within the population and the investment of resources to address that issue could have the greatest benefits.LIMITATIONS1. GP data for the financial year 1st April 2018 – 31st March 2019 was used in preference to data for the financial year 1st April 2019 – 31st March 2020, as the onset of the COVID19 pandemic during the latter year could have affected the reporting of medical statistics by GPs. However, for 53 GPs (out of 7670) that did not submit data in 2018/19, data from 2019/20 was used instead. Note also that some GPs (997 out of 7670) did not submit data in either year. This dataset should be viewed in conjunction with the ‘Health and wellbeing statistics (GP-level, England): Missing data and potential outliers’ dataset, to determine areas where data from 2019/20 was used, where one or more GPs did not submit data in either year, or where there were large discrepancies between the 2018/19 and 2019/20 data (differences in statistics that were > mean +/- 1 St.Dev.), which suggests erroneous data in one of those years (it was not feasible for this study to investigate this further), and thus where data should be interpreted with caution. Note also that there are some rural areas (with little or no population) that do not officially fall into any GP catchment area (although this will not affect the results of this analysis if there are no people living in those areas).2. Although all of the obesity/inactivity-related illnesses listed can be caused or exacerbated by inactivity and obesity, it was not possible to distinguish from the data the cause of the illnesses in patients: obesity and inactivity are highly unlikely to be the cause of all cases of each illness. By combining the data with data relating to levels of obesity and inactivity in adults and children (see the ‘Levels of obesity, inactivity and associated illnesses: Summary (England)’ dataset), we can identify where obesity/inactivity could be a contributing factor, and where interventions to reduce obesity and increase activity could be most beneficial for the health of the local population.3. It was not feasible to incorporate ultra-fine-scale geographic distribution of populations that are registered with each GP practice or who live within each MSOA. Populations might be concentrated in certain areas of a GP practice’s catchment area or MSOA and relatively sparse in other areas. Therefore, the dataset should be used to identify general areas where there are high levels of cancer, rather than interpreting the boundaries between areas as ‘hard’ boundaries that mark definite divisions between areas with differing levels of cancer.TO BE VIEWED IN COMBINATION WITH:This dataset should be viewed alongside the following datasets, which highlight areas of missing data and potential outliers in the data:Health and wellbeing statistics (GP-level, England): Missing data and potential outliersLevels of obesity, inactivity and associated illnesses (England): Missing dataDOWNLOADING THIS DATATo access this data on your desktop GIS, download the ‘Levels of obesity, inactivity and associated illnesses: Summary (England)’ dataset.DATA SOURCESThis dataset was produced using:Quality and Outcomes Framework data: Copyright © 2020, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital.GP Catchment Outlines. Copyright © 2020, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital. Data was cleaned by Ribble Rivers Trust before use.MSOA boundaries: © Office for National Statistics licensed under the Open Government Licence v3.0. Contains OS data © Crown copyright and database right 2021.Population data: Mid-2019 (June 30) Population Estimates for Middle Layer Super Output Areas in England and Wales. © Office for National Statistics licensed under the Open Government Licence v3.0. © Crown Copyright 2020.COPYRIGHT NOTICEThe reproduction of this data must be accompanied by the following statement:© Ribble Rivers Trust 2021. Analysis carried out using data that is: Copyright © 2020, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital; © Office for National Statistics licensed under the Open Government Licence v3.0. Contains OS data © Crown copyright and database right 2021. © Crown Copyright 2020.CaBA HEALTH & WELLBEING EVIDENCE BASEThis dataset forms part of the wider CaBA Health and Wellbeing Evidence Base.

The dataset contains data collected from patients suffering from cancer-related pain. The features extracted from clinical data (including typical cancer phenomena such as breakthrough pain) and the biosignal acquisitions contributed to the definition of a multidimensional dataset. This unique database can be useful for the characterization of the patient’s pain experience from a qualitative and quantitative perspective. We implemented measurable biosignals-related indicators of the individual’s pain response and of the overall Autonomic Nervous System (ANS) functioning. The most peculiar features extracted from EDA and ECG signals can be adopted to investigate the status and complex functioning of the ANS through the study of sympatho-vagal activations. Specifically, while EDA is mainly related sympathetic activation, the Heart Rate Variability (HRV), which can be derived from ECG recordings, is strictly related to the interplay between sympathetic and parasympathetic functioning.

As far as the EDA signal, two types of analyzes have been performed: (i) the Trough-To-Peak analysis (TTP), or min-max analysis, aimed at measuring the difference between the Skin Conductance (SC) at the peak of a response and its previous minimum within pre-established time-windows; (ii) the Continuous Decomposition Analysis (CDA), aimed at performing a decomposition of SC data into continuous signals of tonic (basic level of conductance) and phasic (short-duration changes in the SC) activity. Before applying the TPP analysis or the CDA, the signal was filtered by means of a fifth-order Butterworth low-pass filter with a cutoff frequency of 1 Hz and downsampled up to 10 Hz to reducing the computational burden of the analysis. The application of TPP and CDA allowed the detection and measurement of SC Responses (SCR) and the following parameters have been calculated for both TPP and CDA methodologies:

• Total number of detected SCRs.
• Maximum value of SCRs [measured in μS].
• Minimum value of SCRs [measured in μS].
• Arithmetic mean of the SCRs [measured in μS].
• Maximum interval between SCRs [measured in ms].
• Minimum interval between SCRs [measured in ms].
• Arithmetic mean of the intervals between SCRs [measured in ms].

Concerning the ECG, the RR series of interbeat intervals (i.e., the time between successive R waves of the QRS complex on the ECG waveform) has been computed to extract time-domain parameters of the HRV. The R peak detection was carried out by adopting the Pan–Tompkins algorithm for QRS detection and R peak identification. The corresponding RR series of interbeat intervals were derived as the difference between successive R peaks.

The ECG-derived RR time series was then filtered by means of a recursive procedure to remove the intervals differing most from the mean of the surrounding RR intervals. Then, both the Time-Domain Analysis (TDA) and Frequency-Domain Analysis (FDA) of the HRV have been carried out to extract the main features characterizing the variability of the heart rhythm. Time-domain parameters are obtained from statistical analysis of the intervals between heart beats and are used to describe how much variability in the heartbeats is present at various time scales.

The parameters computed through the TDA include the following:

• Arithmetic mean of the RR time series [measured in ms].
• The standard deviation of the RR time series [measured in ms].
• Mean value of heart rate [measured in bpm].
• Standard deviation of the heart rate [measured in bpm].
• Root Mean Square of Successive Differences of RR intervals [measured in ms], which is sensitive to high-frequency heart period fluctuations in the respiratory frequency range and has been used as an index of vagal cardiac control.
• Number of successive RR intervals whose difference is higher than 50 ms.
• Percentage of successive RR intervals higher than 50 ms.
• Number of successive RR intervals whose difference is higher than 50 ms.

Frequency-domain parameters reflect the distribution of spectral power across different frequencies bands and are used to assess specific components of HRV (e.g., thermoregulation control loop, baroreflex control loop, and respiration control loop, which are regulated by both sympathetic and vagal nerves of the ANS).
The parameters computed through the FDA have been computed by adopting the Welch's Fourier periodogram method based on the Discrete Fourier Transform (DFT), which allows the expression of the RR series in the discrete frequency domain. However, due to the non-stationarity of the RR series, Welch Fourier periodogram method is used for dealing with non-stationarity. Specifically, Welch's periodogram divides the signal into specific periods of constant length appliying the Fast Fourier Transform (FFT) trasforming individually these parts of the signal. The periodogram is basically a way of estimating power spectral density of a time series.

The FDA parameters include the following:

• Peak value in the Very Low Frequency Band of the HRV power density spectrum [measured in Hz].
• Peak value in the Low Frequency Band of the HRV power density spectrum [measured in Hz].
• Peak value in the High Frequency Band of the HRV power density spectrum [measured in Hz].
• Power in the Very Low Frequency Band of the HRV power density spectrum [measured in ms^2].
• Power in the Low Frequency Band of the HRV power density spectrum [measured in ms^2].
• Power in the High Frequency Band of the HRTotal Power of the HRV power density spectrum [measured in ms^2].
• Total Power of the HRV power density spectrum [measured in ms^2].
• Percentage power in the Very Low Frequency Band of the HRV power density spectrum with respect to the total power.
• Percentage power in the Low Frequency Band of the HRV power density spectrum with respect to the total power.
• Percentage power in the High Frequency Band of the HRV power density spectrum with respect to the total power.
• Normalized power in the Low Frequency Band of the HRV power density spectrum with respect to the sum of LF and HF power.
• Normalized power in the High Frequency Band of the HRV power density spectrum with respect to the sum of LF and HF power.
• Sympathovagal balance measured as the ration between power in LF and power in the LF band.

Population based cancer incidence rates were abstracted from National Cancer Institute, State Cancer Profiles for all available counties in the United States for which data were available. This is a national county-level database of cancer data that are collected by state public health surveillance systems. All-site cancer is defined as any type of cancer that is captured in the state registry data, though non-melanoma skin cancer is not included. All-site age-adjusted cancer incidence rates were abstracted separately for males and females. County-level annual age-adjusted all-site cancer incidence rates for years 2006–2010 were available for 2687 of 3142 (85.5%) counties in the U.S. Counties for which there are fewer than 16 reported cases in a specific area-sex-race category are suppressed to ensure confidentiality and stability of rate estimates; this accounted for 14 counties in our study. Two states, Kansas and Virginia, do not provide data because of state legislation and regulations which prohibit the release of county level data to outside entities. Data from Michigan does not include cases diagnosed in other states because data exchange agreements prohibit the release of data to third parties. Finally, state data is not available for three states, Minnesota, Ohio, and Washington. The age-adjusted average annual incidence rate for all counties was 453.7 per 100,000 persons. We selected 2006–2010 as it is subsequent in time to the EQI exposure data which was constructed to represent the years 2000–2005. We also gathered data for the three leading causes of cancer for males (lung, prostate, and colorectal) and females (lung, breast, and colorectal). The EQI was used as an exposure metric as an indicator of cumulative environmental exposures at the county-level representing the period 2000 to 2005. A complete description of the datasets used in the EQI are provided in Lobdell et al. and methods used for index construction are described by Messer et al. The EQI was developed for the period 2000– 2005 because it was the time period for which the most recent data were available when index construction was initiated. The EQI includes variables representing each of the environmental domains. The air domain includes 87 variables representing criteria and hazardous air pollutants. The water domain includes 80 variables representing overall water quality, general water contamination, recreational water quality, drinking water quality, atmospheric deposition, drought, and chemical contamination. The land domain includes 26 variables representing agriculture, pesticides, contaminants, facilities, and radon. The built domain includes 14 variables representing roads, highway/road safety, public transit behavior, business environment, and subsidized housing environment. The sociodemographic environment includes 12 variables representing socioeconomics and crime. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., L. Messer, K. Rappazzo , C. Gray, S. Grabich , and D. Lobdell. County-level environmental quality and associations with cancer incidence#. Cancer. John Wiley & Sons Incorporated, New York, NY, USA, 123(15): 2901-2908, (2017).

Two datasets that explore causes of death due to cancer in South Africa, drawing on data from the Revised Burden of Disease estimates for the Comparative Risk Factor Assessment for South Africa, 2000. The number and percentage of deaths due to cancer by cause are ranked for persons, males and females in the tables below. Lung cancer is the leading cause of cancer in SA accounting for 17% of all cancer deaths. This is followed by oesophagus Ca which accounts for 13%, cervix cancer accounting for 8%, breast cancer accounting for 8% and liver cancer which accounts for 6% of all cancers. Many more males suffer from lung and oesophagus cancer than females.

The number of new cases, age-standardized rates and average age at diagnosis of cancers diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Cancer incidence rates are age-standardized using the direct method and the final 2011 Canadian postcensal population structure. Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

Cervical cancer is one of the leading causes of cancer-related deaths among women worldwide. Early detection and accurate prediction of cervical cancer can significantly improve the chances of successful treatment and save lives. This dataset help to develop a predictive model using machine learning techniques to identify individuals at high risk of cervical cancer, allowing for timely intervention and medical care.

Background

Sarcomas are uncommon cancers that can affect any part of the body. There are many different types of sarcoma and subtypes can be grouped into soft tissue or bone sarcomas. About 15 people are diagnosed every day in the UK. 3 in every 200 people with cancer in the UK have sarcoma.

A highly granular dataset with a confirmed sarcoma event including hospital presentation, serial physiology, demography, treatment prescribed and administered, prescribed and administered drugs. The infographic includes data from 27/12/2004 to 31/12/2021 but data is available from the past 10 years+.

PIONEER geography: The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix.

EHR. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & an expanded 250 ITU bed capacity during COVID. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Scope: All hospitalised patients from 2004 onwards, curated to focus on Sarcoma. Longitudinal & individually linked, so that the preceding & subsequent health journey can be mapped & healthcare utilisation prior to & after admission understood. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to acute care process (timings, staff grades, specialty review, wards and triage). Along with presenting complaints, outpatients admissions, microbiology results, referrals, procedures, therapies, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations and others), and all blood results (urea, albumin, platelets, white blood cells and others). Includes all prescribed & administered treatments and all outcomes. Linked images are also available (radiographs, CT scans, MRI).

Available supplementary data: Matched controls; ambulance, OMOP data, synthetic data.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

Age-standardised rate of mortality from oral cancer (ICD-10 codes C00-C14) in persons of all ages and sexes per 100,000 population.RationaleOver the last decade in the UK (between 2003-2005 and 2012-2014), oral cancer mortality rates have increased by 20% for males and 19% for females1Five year survival rates are 56%. Most oral cancers are triggered by tobacco and alcohol, which together account for 75% of cases2. Cigarette smoking is associated with an increased risk of the more common forms of oral cancer. The risk among cigarette smokers is estimated to be 10 times that for non-smokers. More intense use of tobacco increases the risk, while ceasing to smoke for 10 years or more reduces it to almost the same as that of non-smokers3. Oral cancer mortality rates can be used in conjunction with registration data to inform service planning as well as comparing survival rates across areas of England to assess the impact of public health prevention policies such as smoking cessation.References:(1) Cancer Research Campaign. Cancer Statistics: Oral – UK. London: CRC, 2000.(2) Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-7. (3) La Vecchia C, Tavani A, Franceschi S et al. Epidemiology and prevention of oral cancer. Oral Oncology 1997; 33: 302-12.Definition of numeratorAll cancer mortality for lip, oral cavity and pharynx (ICD-10 C00-C14) in the respective calendar years aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+). This does not include secondary cancers or recurrences. Data are reported according to the calendar year in which the cancer was diagnosed.Counts of deaths for years up to and including 2019 have been adjusted where needed to take account of the MUSE ICD-10 coding change introduced in 2020. Detailed guidance on the MUSE implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causeofdeathcodinginmortalitystatisticssoftwarechanges/january2020Counts of deaths for years up to and including 2013 have been double adjusted by applying comparability ratios from both the IRIS coding change and the MUSE coding change where needed to take account of both the MUSE ICD-10 coding change and the IRIS ICD-10 coding change introduced in 2014. The detailed guidance on the IRIS implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/impactoftheimplementationofirissoftwareforicd10causeofdeathcodingonmortalitystatisticsenglandandwales/2014-08-08Counts of deaths for years up to and including 2010 have been triple adjusted by applying comparability ratios from the 2011 coding change, the IRIS coding change and the MUSE coding change where needed to take account of the MUSE ICD-10 coding change, the IRIS ICD-10 coding change and the ICD-10 coding change introduced in 2011. The detailed guidance on the 2011 implementation is available at https://webarchive.nationalarchives.gov.uk/ukgwa/20160108084125/http://www.ons.gov.uk/ons/guide-method/classifications/international-standard-classifications/icd-10-for-mortality/comparability-ratios/index.htmlDefinition of denominatorPopulation-years (aggregated populations for the three years) for people of all ages, aggregated into quinary age bands (0-4, 5-9, …, 85-89, 90+)

This dataset contains data about lung cancer Mortality. This database is a comprehensive collection of patient information, specifically focused on individuals diagnosed with cancer. It is designed to facilitate the analysis of various factors that may influence cancer prognosis and treatment outcomes. The database includes a range of demographic, medical, and treatment-related variables, capturing essential details about each patient's condition and history.

Key components of the database include:

Demographic Information: Basic details about the patients such as age, gender, and country of residence. This helps in understanding the distribution of cancer cases across different populations and regions.

Medical History: Information about each patient’s medical background, including family history of cancer, smoking status, Body Mass Index (BMI), cholesterol levels, and the presence of other health conditions such as hypertension, asthma, cirrhosis, and other cancers. This section is crucial for identifying potential risk factors and comorbidities.

Cancer Diagnosis: Detailed data about the cancer diagnosis itself, including the date of diagnosis and the stage of cancer at the time of diagnosis. This helps in tracking the progression and severity of the disease.

Treatment Details: Information regarding the type of treatment each patient received, the end date of the treatment, and the outcome (whether the patient survived or not). This is essential for evaluating the effectiveness of different treatment approaches.

The structure of the database allows for in-depth analysis and research, making it possible to identify patterns, correlations, and potential causal relationships between various factors and cancer outcomes. It is a valuable resource for medical researchers, epidemiologists, and healthcare providers aiming to improve cancer treatment and patient care.

id: A unique identifier for each patient in the dataset. age: The age of the patient at the time of diagnosis. gender: The gender of the patient (e.g., male, female). country: The country or region where the patient resides. diagnosis_date: The date on which the patient was diagnosed with lung cancer. cancer_stage: The stage of lung cancer at the time of diagnosis (e.g., Stage I, Stage II, Stage III, Stage IV). family_history: Indicates whether there is a family history of cancer (e.g., yes, no). smoking_status: The smoking status of the patient (e.g., current smoker, former smoker, never smoked, passive smoker). bmi: The Body Mass Index of the patient at the time of diagnosis. cholesterol_level: The cholesterol level of the patient (value). hypertension: Indicates whether the patient has hypertension (high blood pressure) (e.g., yes, no). asthma: Indicates whether the patient has asthma (e.g., yes, no). cirrhosis: Indicates whether the patient has cirrhosis of the liver (e.g., yes, no). other_cancer: Indicates whether the patient has had any other type of cancer in addition to the primary diagnosis (e.g., yes, no). treatment_type: The type of treatment the patient received (e.g., surgery, chemotherapy, radiation, combined). end_treatment_date: The date on which the patient completed their cancer treatment or died. survived: Indicates whether the patient survived (e.g., yes, no).

This dataset contains artificially generated data with as close a representation of reality as possible. This data is free to use without any licence required.

Good luck Gakusei!

Rapid Cancer Registration Data (RCRD) provides a quick, indicative source of cancer data. It is provided to support the planning and provision of cancer services. The data is based on a rapid processing of cancer registration data sources, in particular on Cancer Outcomes and Services Dataset (COSD) information. In comparison, National Cancer Registration Data (NCRD) relies on additional data sources, enhanced follow-up with trusts and expert processing by cancer registration officers. The Rapid Cancer Registration Data (RCRD) may be useful for service improvement projects including healthcare planning and prioritisation. However, it is poorly suited for epidemiological research due to limitations in the data quality and completeness.

Pancreatic cancer is an extremely deadly type of cancer. Once diagnosed, the five-year survival rate is less than 10%. However, if pancreatic cancer is caught early, the odds of surviving are much better. Unfortunately, many cases of pancreatic cancer show no symptoms until the cancer has spread throughout the body. A diagnostic test to identify people with pancreatic cancer could be enormously helpful.

The dataset contains information of 213 cancer patients undergoing clinical or surgical treatment characterized on sociodemographic and clinical data as well as data from the Care Transition Measure (CTM 15-Brazil). Data collection was carried out 7 to 30 days after their discharge from hospital from June to August 2019. Understanding these data can contribute to improving quality of care transitions and avoiding hospital readmissions. To this end, this dataset contains a broad array of variables:

*gender

*age group

*place of residence

*race

*marital status

*schooling

*paid work activity

*type of treatment

*cancer staging

*metastasis

*comorbidities

*main complaint

*continue use medication

*diagnosis

*cancer type

*diagnostic year

*oncology treatment

*first hospitalization

*readmission in the last 30 days

*number of hospitalizations in the last 30 days

*readmission in the last 6 months

*number of hospitalizations in the last 6 months

*readmission in the last year

*number of hospitalizations in the last year

*questions 1-15 from CTM 15-Brazil

The data are presented as a single Excel XLSX file: cancer patient´s care transitions dataset.xlsx.

The analyses of the present dataset have the potential to generate hospital readmission prevention strategies to be implemented by the hospital team. Researchers who are interested in CTs of cancer patients can extensively explore the variables described here.

The project from which these data were extracted was approved by the institution’s research ethics committee (approval n. 3.266.259/2019) at Associação Hospital de Caridade Ijuí, Rio Grande do Sul, Brazil.

Number and percentage of patients by stage at diagnosis for Breast, Colorectal and Lung cancer by NHS Board of residence, Cancer networks and Scotland. Numbers for the 3-cancers combined for 2010 and 2011 to provide baseline data to support the HEAT Decect Cancer Early (DCE) target.

Source agency: ISD Scotland (part of NHS National Services Scotland)

Designation: Official Statistics not designated as National Statistics

Language: English

Alternative title: Detect cancer early

Analysis of ‘Breast Cancer Dataset’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://www.kaggle.com/yasserh/breast-cancer-dataset on 28 January 2022.

--- Dataset description provided by original source is as follows ---

Description:

Breast cancer is the most common cancer amongst women in the world. It accounts for 25% of all cancer cases, and affected over 2.1 Million people in 2015 alone. It starts when cells in the breast begin to grow out of control. These cells usually form tumors that can be seen via X-ray or felt as lumps in the breast area.

The key challenges against it’s detection is how to classify tumors into malignant (cancerous) or benign(non cancerous). We ask you to complete the analysis of classifying these tumors using machine learning (with SVMs) and the Breast Cancer Wisconsin (Diagnostic) Dataset.

Acknowledgements:

This dataset has been referred from Kaggle.

Objective:

• Understand the Dataset & cleanup (if required).
• Build classification models to predict whether the cancer type is Malignant or Benign.
• Also fine-tune the hyperparameters & compare the evaluation metrics of various classification algorithms.

--- Original source retains full ownership of the source dataset ---

About Dataset 📌 Overview This dataset has been carefully synthesized to support research in lung cancer survival prediction, enabling the development of models that estimate:

Whether a patient is likely to survive at least one year post-diagnosis (Binary Classification). The probability of survival based on clinical and lifestyle factors (Regression Analysis). The dataset is designed for machine learning and deep learning applications in medical AI, oncology research, and predictive healthcare.

📜 Dataset Generation Process The dataset was generated using a combination of real-world epidemiological insights, medical literature, and statistical modeling. The feature distributions and relationships have been carefully modeled to reflect real-world clinical scenarios, ensuring biomedical validity.

📖 Medical References & Sources The dataset structure is based on well-established lung cancer risk factors and survival indicators documented in leading medical research and clinical guidelines:

World Health Organization (WHO) Reports on lung cancer epidemiology. National Cancer Institute (NCI) & American Cancer Society (ACS) guidelines on lung cancer risk factors and treatment outcomes. The IASLC Lung Cancer Staging Project (8th Edition): Standard reference for lung cancer staging. Harrison’s Principles of Internal Medicine (20th Edition): Provides an in-depth review of lung cancer diagnosis and treatment. Lung Cancer: Principles and Practice (2022, Oxford University Press): Clinical insights into lung cancer detection, treatment, and survival factors. 🔬 Features of the Dataset Each record in the dataset represents an individual’s clinical condition, lifestyle risk factors, and survival outcome. The dataset includes the following features:

1️⃣ Patient Demographics Age → A key risk factor for lung cancer progression and survival. Gender → Male and female lung cancer survival rates can differ. Residence → Urban vs. Rural (impact of environmental factors). 2️⃣ Risk Factors & Lifestyle Indicators These factors have been linked to lung cancer risk in epidemiological studies:

Smoking Status → (Current Smoker, Former Smoker, Never Smoked). Air Pollution Exposure → (Low, Moderate, High). Biomass Fuel Use → (Yes/No) – Associated with household air pollution. Factory Exposure → (Yes/No) – Industrial exposure increases lung cancer risk. Family History → (Yes/No) – Genetic predisposition to lung cancer. Diet Habit → (Vegetarian, Non-Vegetarian, Mixed) – Nutritional impact on cancer progression. 3️⃣ Symptoms (Primary Predictors) These are key clinical indicators associated with lung cancer detection and severity:

Hemoptysis (Coughing Blood) Chest Pain Fatigue & Weakness Chronic Cough Unexplained Weight Loss 4️⃣ Tumor Characteristics & Clinical Features Tumor Size (mm) → The size of the detected tumor. Histology Type → (Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma). Cancer Stage → (Stage I to Stage IV). 5️⃣ Treatment & Healthcare Facility Treatment Received → (Surgery, Chemotherapy, Radiation, Targeted Therapy). Hospital Type → (Private, Government, Medical College). 6️⃣ Target Variables (Predicted Outcomes) Survival (Binary) → 1 (Yes) if the patient survives at least 1 year, 0 (No) otherwise. Survival Probability (%) (Can be derived) → Estimated probability of survival within one year. ⚡ Why This Dataset is Valuable? ✅ Balanced Data Distribution Designed to ensure a representative distribution of lung cancer survival cases. Prevents model bias and improves generalization in predictive models. ✅ Medically-Inspired Feature Engineering Features are derived from real-world lung cancer risk factors, validated through medical literature. Incorporates both lifestyle and clinical indicators to enhance predictive accuracy.(no real person data is used,just have made an biomedical environment) ✅ Diverse Risk Factors Considered Smoking, air pollution, and genetic history as primary lung cancer contributors. Symptom severity and tumor histology influence survival rates. ✅ Scalability & ML Suitability Ideal for classification and regression tasks in machine learning. Can be used with deep learning (TensorFlow, PyTorch), ML models (XGBoost, Random Forest, SVM), and explainable AI techniques like SHAP and LIME. 📂 Dataset Usage & Applications This dataset is highly useful for multiple healthcare AI applications, including:

🩺 Predictive Analytics → Early detection of high-risk lung cancer patients. 🤖 Healthcare Chatbots → AI-powered risk assessment tools.